Cargando…
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer
Immunotherapy is acquiring a primary role in treating endometrial cancer (EC) with a relevant benefit for many patients. Regardless, patients progressing during immunotherapy or those who are resistant represent an unmet need. The mechanisms of immune resistance and escape need to be better investig...
Autores principales: | Passarelli, Anna, Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Rossetti, Sabrina, Tambaro, Rosa, Ventriglia, Jole, Gherardi, Federica, Iannacone, Eva, Venanzio, Sergio Setola, Fiore, Francesco, Bartoletti, Michele, Scognamiglio, Giosuè, Califano, Daniela, Pignata, Sandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479093/ https://www.ncbi.nlm.nih.gov/pubmed/36119020 http://dx.doi.org/10.3389/fimmu.2022.953115 |
Ejemplares similares
-
The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2023) -
Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
por: Di Napoli, Marilena, et al.
Publicado: (2022) -
Ovarian cancer standard of care: are there real alternatives?
por: Pepa, Chiara Della, et al.
Publicado: (2015) -
Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013) -
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)